Epigenomics' Epi proColon Blood Test Finally Makes The Grade With FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA approved the first blood-based colorectal cancer screening test, developed by Epigenomics, after a challenging regulatory path for the product, including a 2014 not-approvable letter.
You may also be interested in...
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test
CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.
Global Medtech Guidance Tracker: February 2021
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: